
A Phase Ib study of NUC-3373, a targeted inhibitor of thymidylate Jordan Berlin¹, Andrew L. Coveler², Kristen K Ciombor¹, Farasat Kazmi³, Janet S Graham⁴, Mary Linton Peters⁵, Jeffrey W Clark⁶, Michelle Myers⁷, Aimery de Gramont⁸, T.R. Jeffry Evans⁴, Sarah P Blagden³ synthase, in combination with standard therapies in patients with Vanderbilt University Medical Center, Nashville, TN, USA Seattle Cancer Care Alliance/University of Washington, Seattle, WA, US 3) Early Phase Clinical Trials Unit, Churchill Hospital, University of Oxford, Oxford, UK 4) Beatson West of Scotland Cancer Centre/University of Glasgow, Glasgow, UK 5) Beth Israel Deaconess Medical Center, Boston, MA, US advanced colorectal cancer (NuTide:302) 6) Massachusetts General Hospital, Boston, MA, US 7) NuCana plc, Edinburgh, UK 8) Franco-British Institute, Levallois-Perret, France

BACKGROUND

- CRC 3rd most common cancer
 Incidence: 1.8 million
 Annual deaths: 880,000¹
- 5-FU remains the cornerstone of treatment for CRC, despite having several limitations
- Rapidly degraded by DPD²
- Short plasma half-life (8-14 mins)³ necessitates prolonged (46 hour) infusions
- Generation of toxic catabolites such as FBAL and FUTP
- Cell entry requires nucleoside transporters
- Complex enzymatic activation

NUC-3373 bypasses the key cancer resistance pathways associated with 5-FU



NUC-3373: A targeted inhibitor of TS

- ProTide transformation of FUDR-MP^{4,5}, the active anti-cancer metabolite of 5-FU
- Resistant to breakdown by DPD
- Able to enter cells independently of nucleoside transporters
- Low levels of toxic catabolites (FBAL, FUTP)
- Generates high levels of FUDR-MP⁶, which binds to TS
- Causes an imbalance in the nucleotide pool leading to DNA damage and cell death
- Induces ER stress and DAMP release leading to immunogenic cell death⁷⁻⁹

NuTide:301 (NUC-3373 monotherapy)

- Phase I first-in-human, dose-escalation study in patients with advanced solid tumors
- MTD established (2,500 mg/m²)
- Well-tolerated and encouraging signs of activity

NuTide:302 study

Originally designed to investigate NUC-3373 based combinations in heavily pre-treated CRC patients

Part I

Assessed NUC-3373 ± leucovorin (LV) Q1W & Q2W NUC-3373 IV infusion: 1500 mg/m² given over 2 hours; 2500 mg/m² given over 4 hours

Part II

To investigate increasing doses of NUC-3373 + LV Q1W in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI)

Active and recruiting

Part III

Designed to establish optimal combinations of NUFOX/NUFIRI with VEGF and EGFR pathway inhibitors

RESULTS (Part I)

- 38 patients; age 33-75 (median; 58)
- Heavily pre-treated; median 4 prior lines (range 2-13)

Favorable safety profile in heavily pre-treated population

	NUC-3373 (n=38)*		5-FU IV (n=143)10		5-FU Bolus (n=593)11		Capecitabine (n=596)11	
Category	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%)	All Grades (%)	G3 or G4 (%
Neutropenia	0	0	48	13	46	21	13	3
Anemia	18	5	91	2	79	2	80	3
Diarrhea	32	0	45	6	61	12	55	15
Nausea	45	5	55	4	51	4	43	4
Vomiting	42	0	32	3	30	5	27	5
Mucositis/Stomatitis	11	0	29	3	62	15	25	3
Hand-foot syndrome	0	0	13	1	6	1	54	17
Dermatitis	11	0	20	0	26	1	27	1
Fatigue/asthenia	47	5	48	4	46	4	42	4
Elevated bilirubin	11	5	36	11	17	6	48	23
	Heavily pre-treated patients NUC-3373 ± LV Q1W or Q2W		First-line patients 5-FU/LV infusional days 1&2, Q2W		First-line patients 5-FU/LV bolus days 1-5, Q4W		First-line patients Capecitabine BID, 2wks on, 1wk off	

- Grade 4 treatment-related AE (1x elevated bilirubin)
- Grade 3 treatment-related AEs (2x elevated ALT, 2x elevated ALP, 2x nausea, 2x anemia, 1x elevated AST, 1x hyponatremia, 1x fever, 1x fatigue)
- No FBAL (hand-foot syndrome) or FUTP¹² (neutropenia or diarrhea) associated Grade 3 or 4 AEs
- LV did not affect the safety or PK profile of NUC-3373 * NUC-3373 All-cause adverse events, selected relevant to comparator data

Encouraging efficacy signals observed in heavily pre-treated CRC patients Selected case studies in patients who achieved \geq 3 months on study

987 Cancer Research; 47:2203-2206 4. McGuigan C et al., 2011 Med Chem; 27:7247-7258 5. Vande Voorde J et al., 2011 Blochem Pharmacol; 82:441-452 6. Ghazaly E et al., 2017 Ann Oncol; Suppl_5:128 7. McKissock F et al., 2016 Classical Science of adverse reactions in 25 m charlents) 12. Buitcher E et al. 2018 Classical Science 2016;522-624

				Scietted tase studies in patients who achieved
M	lutational Status	Duration of Last Treatment	Sites of Disease	—
69 YEARS Prior Lines 2	RAS unknown	1.5 months	liver	1500 q1w
			peritopeum	
47 YEARS Prior Lines 4	RAS wt	3 months	peritoneum lymph nodes liver	1500 q1w
	DAG 1		luna	
52 YEARS Prior Lines 5	RAS wt BRAF mt	(3 months	lung liver	1500 q2w
	DAG			
48 YEARS Prior Lines 4	RAS mt	(15 months	illacus muscle	2500 q1w
2	RAS			
69 YEARS Prior Lines 4	unknown	(3 months	liver peritoneum	2500 q1w
	RAS			
65 YEARS Prior Lines 3	mt	(6 months	liver	1500 q2w
	RAS			
57 YEARS Prior Lines 4	unknown	1 month	lung	1500 q1w
	RAS		peritoneum	
67 YEARS Prior Lines 3	unknown	3 months	pentoneum	2500 q1w
59 YEARS	RAS wt	(3 months)	lung	1500
59 YEARS Prior Lines 7	wt	months	lymph nodes	d2m
67 YEARS	RAS	2 months	liver	1500
67 YEARS Prior Lines 5	mt	months	abdominal wall	1500 q1w
75 YEARS	RAS mt	unknown	liver	1500
75 YEARS Prior Lines 4	mt	\bigcirc	iivei	q2w

- 40% reduction in target lesion (adj. CAPOX 3 months; FOLFIRI 3 months; Lonsurf 3 months; NUC-3373 [-40%] 3.5 months)
- 28% reduction in overall tumor burden; fluoropyrimidine refractory patient (CAPOX [+35%] 2 months; FOLFIRI PD 1.5 months; NUC-3373 [-28%] 5.1 months)
- 15% reduction in overall tumor burden; heavily pretreated patient with BRAF mutation (5 prior lines)

No: 475P NCT No: NCT03428958 EudraCT Number: 2017-002062-53 Email: michellemyers@nucana.com






NuTide:302 amendment

- Based on encouraging safety, PK and efficacy signals in heavily pre-treated patients (Part I), protocol was expanded
- Inclusion of less heavily pre-treated patient population
- Second-line patients
- Updated from Phase Ib to Phase Ib/II
- Protocol amendment approved in USA, UK and France

Expanded Phase Ib/II study design



Additional cohorts may be opened.

Current study status

- Part I recruitment complete
- Part II (Arms 2a & 2b) ongoing

CONCLUSION

- NUC-3373 is a targeted TS inhibitor designed to overcome the key cancer resistance mechanisms associated with 5-FU
- NUC-3373 has the potential to offer enhanced efficacy, an improved safety profile and a more convenient dosing regimen compared to 5-FU
- NuTide:302 has been expanded to a Phase Ib/II study and allows enrollment of second-line CRC patients
- A registrational study of NUC-3373 for the second-line treatment of patients with CRC is planned (NuTide:323)